Skip to search formSkip to main contentSkip to account menu

pracinostat

Known as: 2-propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1h-benzimidazol-5-yl)-N-hydroxy-, (2E)-, kaempferol 3-o-beta-d-(6-E-P-coumaroylglucoside) 
An orally available, small-molecule histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Pracinostat inhibits HDACs, which… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent Terminology

Narrower (1)

SB939

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Phase II study of lower-dose pracinostat plus azacitidine safety and efficacy in patients with high/very high-risk myelodysplastic syndromes.
7556Background: Hypomethylating agents (HMA), such as azacitidine (AZA), are the standard of care for patients (pts) with higher… 
Review
2019
Review
2019
Recent Prospectives of Anticancer Histone Deacetylase Inhibitors
Histone deacetylases (HDACs) are common targets for cancer therapy as they are expressed in many forms of cancers; several… 
2019
2019
Phase I Study of Pracinostat in Combination with Gemtuzumab Ozogamicin (PraGO) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Background: Relapsed/Refractory AML (RR-AML) represents an area in urgent need for new treatments, particularly among patients… 
2019
2019
Drug repurposing screen identifies novel classes of drugs with anticancer activity in mantle cell lymphoma.
AIM AND OBJECTIVE Mantle cell lymphoma (MCL) is typically an aggressive and rare disease with poor prognosis, therefore new… 
2019
2019
A Phase 3 Randomized Study (PRIMULA) of the Epigenetic Combination of Pracinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, with Azacitidine (AZA) in Patients with Newly Diagnosed Acute Myeloid…
Background: AML is associated with poor survival rates in patients ineligible for IC or stem cell transplant due to advanced age… 
2018
2018
A phase 3, randomized study of pracinostat (PRAN) in combination with azacitidine (AZA) versus placebo in patients ≥18 years with newly diagnosed acute myeloid leukemia (AML) unfit for standard…
TPS7078Background: AML is associated with poor survival rates in patients ineligible for IC or stem cell transplant due to… 
2018
2018
Planned Interim Analysis of a Phase 2 Study Evaluating the Combination of Pracinostat, a Histone Deacetylase Inhibitor (HDACi), and Azacitidine in Patients with High/Very High-Risk Myelodysplastic…
Introduction: Higher risk MDS is a serious disease associated with poor survival with hypomethylating agents (HMAs) the… 
2017
2017
The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia
Chronic myeloid leukemia (CML) treatment has been improved by tyrosine kinase inhibitors (TKIs) such as imatinib mesylate (IM… 
Review
2016
Review
2016
A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit
Background: Pracinostat, a potent oral Class I, II, IV histone deacetylase (HDAC) inhibitor, exhibited modest single-agent… 
2014
2014
Pracinostat in Combination with Azacitidine Produces a High Rate and Rapid Onset of Disease Remission in Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Background: Pracinostat is a potent oral inhibitor of histone deacetylases (HDAC’s), selective for class I, II and IV isoforms… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)